These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18221117)

  • 21. Cilostazol.
    Sorkin EM; Markham A
    Drugs Aging; 1999 Jan; 14(1):63-71; discussion 72-3. PubMed ID: 10069409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cilostazol and peripheral arterial disease.
    Pearce L; Ghosh J; Counsell A; Serracino-Inglott F
    Expert Opin Pharmacother; 2008 Oct; 9(15):2683-90. PubMed ID: 18803454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of cilostazol prescribed in a pragmatic treatment program for intermittent claudication.
    Lee C; Nelson PR
    Vasc Endovascular Surg; 2014 Apr; 48(3):224-9. PubMed ID: 24399131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication.
    Stone WM; Demaerschalk BM; Fowl RJ; Money SR
    J Stroke Cerebrovasc Dis; 2008; 17(3):129-33. PubMed ID: 18436153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial.
    Dawson DL; Cutler BS; Meissner MH; Strandness DE
    Circulation; 1998 Aug; 98(7):678-86. PubMed ID: 9715861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Makar RR; Young IS; Lee B; Soong CV
    Vasc Endovascular Surg; 2009; 43(2):132-43. PubMed ID: 19131370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cilostazol and outcome in outpatients with peripheral artery disease.
    Perez P; Esteban C; Sauquillo JC; Yeste M; Manzano L; Mujal A; Jiménez Caballero PE; Aguilar E; Sánchez Muñoz-Torrero JF; Monreal M;
    Thromb Res; 2014 Aug; 134(2):331-5. PubMed ID: 24951338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cilostazol: improving walking distance in patients with intermittent claudication.
    Collinson DJ; Donnelly R
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):503-9. PubMed ID: 15225110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effects of cilostazol and other therapies for intermittent claudication.
    Dawson DL
    Am J Cardiol; 2001 Jun; 87(12A):19D-27D. PubMed ID: 11434896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of cilostazol in the treatment of intermittent claudication.
    Barnett AH; Bradbury AW; Brittenden J; Crichton B; Donnelly R; Homer-Vanniasinkam S; Mikhailidis DP; Stansby G
    Curr Med Res Opin; 2004 Oct; 20(10):1661-70. PubMed ID: 15462700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of peripheral arterial disease and intermittent claudication.
    Schainfeld RM
    J Am Board Fam Pract; 2001; 14(6):443-50. PubMed ID: 11757887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cilostazol: a novel treatment option in intermittent claudication.
    Cariski AT
    Int J Clin Pract Suppl; 2001 Apr; (119):11-8. PubMed ID: 11355274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease.
    Bramer SL; Forbes WP; Mallikaarjun S
    Clin Pharmacokinet; 1999; 37 Suppl 2():1-11. PubMed ID: 10702882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication.
    Thompson PD; Zimet R; Forbes WP; Zhang P
    Am J Cardiol; 2002 Dec; 90(12):1314-9. PubMed ID: 12480040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication.
    Lee TM; Su SF; Tsai CH; Lee YT; Wang SS
    Clin Sci (Lond); 2001 Sep; 101(3):305-11. PubMed ID: 11524048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment with pharmacological agents in peripheral arterial disease patients does not result in biomechanical gait changes.
    Huisinga JM; Pipinos II; Stergiou N; Johanning JM
    J Appl Biomech; 2010 Aug; 26(3):341-8. PubMed ID: 20841626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cilostazol is effective and safe option for the treatment of intermittent claudication. Results of the NOCLAUD study].
    Farkas K; Járai Z; Kolossváry E
    Orv Hetil; 2017 Jan; 158(4):123-128. PubMed ID: 28116935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication.
    Elam MB; Heckman J; Crouse JR; Hunninghake DB; Herd JA; Davidson M; Gordon IL; Bortey EB; Forbes WP
    Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1942-7. PubMed ID: 9848888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The limits of evidence in drug approval and availability: a case study of cilostazol and naftidrofuryl for the treatment of intermittent claudication.
    Hong H; Mackey WC
    Clin Ther; 2014 Aug; 36(8):1290-301. PubMed ID: 25012728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological treatment of intermittent claudication does not have a significant effect on gait impairments during claudication pain.
    Yentes JM; Huisinga JM; Myers SA; Pipinos II; Johanning JM; Stergiou N
    J Appl Biomech; 2012 May; 28(2):184-91. PubMed ID: 22723116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.